Is it effective to take one pill of ixazomib every 20 days?
Ixazomib (Ixazomib) is a drug used to treat multiple myeloma. Based on current clinical research and usage experience, it is usually recommended that patients take ixazomib orally every other week for four consecutive weeks as a treatment cycle. After each treatment cycle, there will be a withdrawal period for rest and recovery. According to the description, one pill of ixazomib is taken every 20 days, which is different from the conventional treatment plan. Therefore, it is impossible to determine whether this frequency of administration can achieve good therapeutic effects.
The dosage and frequency of ixazomib use need to be determined based on the patient's specific condition and physician recommendations. If the dose is insufficient or the frequency is not high enough, the therapeutic effect may be affected; if the dose is too high or the frequency is too high, adverse reactions and side effects may occur. Ixazomib is available by prescription only, and treatment must be initiated and monitored by a physician experienced in the management of multiple myeloma. Ixazomib is available in capsule form (2.3, 3 and 4 mg) and should be taken at least one hour before or two hours after a meal.
The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)